When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

急性前列腺炎

最后审阅: 5 Oct 2024
最后更新: 25 Mar 2022

小结

定义

病史和体格检查

关键诊断因素

  • 存在的危险因素
  • 发热、寒颤、不适感
  • 前列腺触痛
完整详情

其他诊断因素

  • 年龄<50岁
  • 尿频
  • 排尿困难
  • 尿流变细
  • 会阴疼痛
  • 温暖或柔软、呈沼泽样的腺体
  • 留置导尿管
  • 近期经直肠前列腺活组织检查
  • 近期经尿道手术
完整详情

危险因素

  • 泌尿道感染(UTI)
  • 良性前列腺肥大
  • 泌尿道器械操作/手术操作
  • 总体健康状况差/免疫抑制
  • 吸烟和酒精摄入
  • 遗传学
完整详情

诊断性检查

首要检查

  • 尿液分析
  • 尿液培养
  • 血培养
完整详情

需考虑的检查

  • 经直肠超声
  • 四杯法或两杯法
完整详情

新兴检查

  • 尿液细胞学检查
  • 膀胱镜检查
  • 前列腺活组织检查

治疗流程

急症处理

出现脓毒症体征

无脓毒症体征

撰稿人

作者

Christopher Chapple, BSc, MD, FRCS (Urol), FEBU

Honorary Senior Lecturer of Urology

University of Sheffield

Consultant Urological Surgeon

Department of Urology

Royal Hallamshire Hospital

Sheffield

UK

利益声明

CC is a consultant for Astellas, Contura, Ferring, Symimetic, Takeda, and Urovant Sciences. He is an author for Astellas and Ferring. He is an investigator for Allergan, Astellas, Ferring, Poesis Medical, and Bayer. He is a co-patent holder for Symimetic. He is a speaker for Allergan and Astellas.

Altaf Mangera, MBChB (Hons), MD, FRCS (Urol)

Consultant Urologist

Department of Urology

Royal Hallamshire Hospital

Sheffield

UK

利益声明

AM declares that he has no competing interests.

鸣谢

Dr Christopher Chapple and Dr Altaf Mangera would like to gratefully acknowledge the contribution of Robyn Webber MB, ChB, MD, FRCSEd (Urol) to this topic. Not disclosed.

同行评议者

Hans Hedelin, MD

Department of Urology and Centre for Research and Development

Karnsjukhuset

Skovde

Sweden

利益声明

HH declares that he has no competing interests.

Benjamin A. Lipsky, MD, FACP, FIDSA, FRCP

Professor of Medicine

University of Washington

VA Puget Sound Health Care System

Seattle

WA

利益声明

BAL has received research funding from, and been a consultant to, several pharmaceutical companies that make antibiotic agents that might be used for treating bacterial prostatitis.

内容使用需遵循免责声明